Maximizing the Impact of Microphysiological Systems with in Vitro–in Vivo Translation
Name
c8lc00039e.pdf
Size
889.95 KB
Format
Adobe PDF
Checksum (MD5)
8a79865422887b1f0e0e70a62a8e98d2
Author(s)
Stokes, Cynthia L.
Cirit, Murat
Date Issued
June 2018
Journal
Lab on a Chip
Publisher
Royal Society of Chemistry (RSC)
Citation
Cirit, Murat, and Cynthia L. Stokes. “Maximizing the Impact of Microphysiological Systems with in Vitro–in Vivo Translation.” Lab on a Chip 18, 13 (2018): 1831–1837 © 2018 Royal Society of Chemistry
Version
Final published version
Abstract
Microphysiological systems (MPS) hold promise for improving therapeutic drug approval rates by providing more physiological, human-based, in vitro assays for preclinical drug development activities compared to traditional in vitro and animal models. Here, we first summarize why MPSs are needed in pharmaceutical development, and examine how MPS technologies can be utilized to improve preclinical efforts. We then provide the perspective that the full impact of MPS technologies will be realized only when robust approaches for in vitro-in vivo (MPS-to-human) translation are developed and utilized, and explain how the burgeoning field of quantitative systems pharmacology (QSP) can fill that need.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-NonCommercial 3.0 Unported
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1039/c8lc00039e
